Furosemide
Brand names: Furoscix, Furosemide, Lasix
At a glance
- Medicare prescriptions, 2024
- 22,239,070
- Medicare drug cost
- $120.0M
- Average cost per prescription
- $5.40
- Clinicians who prescribed it
- 278,862
Where it is prescribed
List the prescribers in any state, county, city or ZIP code →
What it is used for
Edema LASIX is indicated in adults and pediatric patients for the treatment of edema associated with congestive heart failure, cirrhosis of the liver, and renal disease, including the nephrotic syndrome. LASIX is particularly useful when an agent with greater diuretic potential is desired. Hypertension Oral LASIX may be used in adults for the treatment of hypertension alone or in combination with other antihypertensive agents. Hypertensive patients who cannot be adequately controlled with thiazides will probably also not be adequately controlled with LASIX alone.
From the FDA-approved prescribing information (label dated September 2025). Full labels on DailyMed (opens in a new tab)
Who prescribes it
- Family Medicine 26.2%
- Internal Medicine 23.2%
- Nurse Practitioners 19.7%
- Cardiology 10.2%
- Physician Assistants 5.4%
- Interventional Cardiology 3.6%
- Nephrology (Kidney) 3.4%
- Geriatric Medicine 1.9%
- General Practice 1.3%
- Hospitalist 1.1%
- Cardiac Electrophysiology 0.6%
- Pulmonology 0.5%
All prescribers, by place, name or specialty →
Share of Medicare prescriptions written by each specialty. Select one to list its prescribers.
Trend, 2019–2024
Medicare prescriptions fell 9% from 2019 to 2024.
Biggest change by state since 2019
- Utah +7%
- Arizona −2%
- Maryland −3%
- Nevada −3%
- Delaware −3%
- Rhode Island (smallest change) −20%
- New York (smallest change) −19%
From CMS’s yearly state and national Part D summaries, which count every prescriber, including those CMS leaves out of its per-clinician data (fewer than 11 prescriptions). That is why these totals are higher than the count at the top of this page. Prescriptions include refills.
What it looks like
Pills from 2 makers on file. The same medicine can look different depending on who made it, so check the imprint (the letters and numbers on the pill) with your pharmacist if a refill looks different.
A-S Medication Solutions
| Strength | Looks like | Imprint |
|---|---|---|
| 80 mg | white round tablet, 10 mm, scored to split in 2 | 19 0 |
Validus Pharmaceuticals LLC
| Strength | Looks like | Imprint |
|---|---|---|
| 20 mg | white oval tablet, 8 mm | LASIX |
| 40 mg | white round tablet, 8 mm | LASIX 40 |
| 80 mg | white round tablet, 10 mm | LASIX 80 |
Source: DailyMed (U.S. National Library of Medicine), from each maker’s FDA drug listing. A few makers are shown, not every one. Never take a pill you can’t identify; ask a pharmacist.
Industry payments about this drug
Drug makers reported $1.2M in payments to clinicians that named this drug in 2025 (meals, speaking, consulting and similar).
- Scpharmaceuticals Inc. $1.2M
- Shorla Oncology Inc. $270
Source: CMS Open Payments, general payments (not research), program year 2025. A payment is not evidence of wrongdoing. Payments by doctor
Recalls and shortages
On the FDA shortage list now
- Furosemide, Injection, 10 mg/1 mL (NDC 36000-282-25) (Baxter Healthcare)
- Furosemide, Injection, 10 mg/1 mL (NDC 36000-283-25) (Baxter Healthcare)
- Furosemide, Injection, 10 mg/1 mL (NDC 36000-284-25) (Baxter Healthcare)
- Furosemide, Injection, 10 mg/1 mL (NDC 63323-280-02) (Fresenius Kabi USA, LLC)
- Furosemide, Injection, 10 mg/1 mL (NDC 23155-473-41) (Avet Pharmaceuticals, Inc.)
- Furosemide, Injection, 10 mg/1 mL (NDC 23155-473-42) (Avet Pharmaceuticals, Inc.)
- Furosemide, Oral Solution, 10 mg/1 mL (NDC 0054-3294-46) (Hikma Pharmaceuticals USA, Inc.)
- Furosemide, Oral Solution, 10 mg/1 mL (NDC 0054-3294-50) (Hikma Pharmaceuticals USA, Inc.)
2 recalls since 2020
- Mar 2026 · Leading Pharma, LLC · Class II
CGMP Deviations; presence of N-nitroso-Furosemide (NNF) above the recommended intake limit. - Jan 2026 · Graviti Pharmaceuticals Private Limited · Class II
Presence of Foreign Substance
Recalls usually affect specific lots from one maker, not every version of a drug. Class I is the most serious; most drug recalls are Class II. FDA recalls (opens in a new tab)
Sources: CMS Medicare Part D Prescribers by Provider and Drug (2024; prescriptions include refills, and CMS hides counts under 11 per prescriber); U.S. Food and Drug Administration, openFDA (drug labels, NDC directory, enforcement reports, drug shortages); CMS Open Payments 2025; ClinicalTrials.gov. General information only, not medical advice; not yet reviewed by our medical reviewer.